Should we treat newly diagnosed patients with CLL differently after ASH 2019?
Should we treat newly diagnosed patients with CLL differently after ASH 2019?
Related Articles
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Lisocabtagene maraleucel receives European Commission approval for the treatment of adult patients with R/R FL
Lisocabtagene maraleucel has received European Commission approval for the treatment of patients with R/R FL, following positive results from the phase II TRANSCEND FL trial.
Pirtobrutinib receives positive CHMP opinion for the treatment of adult patients with R/R CLL and previous BTKi exposure
On February 28, 2025, the EMA CHMP issued a positive opinion and recommendation for the approval of pirtobrutinib for the treatment of adult patients with…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for the treatment of R/R LBCL
Following positive results from the phase III ECHELON-3 trial, the FDA approves brentuximab vedotin in combination with lenalidomide and rituximab, for the treatment of adult…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
ECHELON-3 subgroup analysis: Brentuximab vedotin + lenalidomide + rituximab for older patients with R/R DLBCL
We summarize key results from a subgroup analysis of the phase III ECHELON-3 trial evaluating the safety and efficacy of BV+Len+R vs Pbo+Len+R in older…
Home | Lymphoma Hub
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari about the latest updates from the inMIND…
POLARIX: 5-year follow-up of Pola-R-CHP in patients with intermediate- or high-risk DLBCL
We summarize key 5-year follow-up results from the phase III POLARIX trial evaluating the safety and efficacy of Pola-R-CHP vs R-CHOP in patients with intermediate-…